No Data
Charles River Announces Endosafe Cartridge Recycling Program, Strengthening Sustainability Commitment
The National Medical Products Administration is seeking opinions: it plans to complete the review and approval of clinical trial applications for qualified innovative drugs within 30 working days.
On June 16, the National Medical Products Administration organized the drafting of the "Announcement on Optimizing Matters Related to the Review and Approval of Clinical Trials for Innovative Drugs (Draft for Public Comments)" based on the experience of its pilot work on optimizing the review and approval of clinical trials for innovative drugs, and is now soliciting public opinions.
Price differences exceed 10 times! The value of domestic innovative drugs has "surged" after going abroad, making the expansion of overseas markets a "required course"?
On June 13, the Financial Association reported (Reporter He Fan) that today Yifan Pharmaceutical (002019.SZ) announced the price of the innovative drug F-627 (Aibegisitin α Injection, US trade name: Ryzneuta) in the US, which is approximately 14 times higher than the domestic price. This is not an isolated case; after successfully passing FDA approval, many domestic innovative drugs have been priced significantly higher after going abroad. Some companies told Financial Association reporters that the pricing in the US is determined based on factors such as local payment levels. Industry experts interviewed believe that the differences in the medical systems of the two countries lead to significant discrepancies in drug pricing.
Short Bets on S&P 500 Healthcare Sector Ease in May; MRNA Stays Most Shorted Stock
Shopify Teams Up With Coinbase, Stripe To Roll Out USDC Stablecoin Payments For Merchants
Megacap Stocks Aren't All up in 2025. But This Chart Shows They've Trounced the S&P 500's Smallest Equities.
